The future of peptides in the US is about to become clearer. Here’s what you should know. The FDA’s Pharmacy Compounding Advisory Committee (PCAC) is scheduled to meet this week to review controversial, popular peptide injections and discuss whether compounding pharmacies should be able to dispense them. This meeting offers an early glimpse into how the second Trump administration’s drug regulators will respond to the rapidly expanding popularity of peptides that have not been FDA-approved. The committee is made up mainly of health professionals who prescribe, produce or promote peptides, unlike previous panels that were largely composed of academics and researchers. US Health and Human Services Secretary Robert F. Kennedy Jr. has expressed his support for peptides and hopes to relax restrictions, but faces resistance within the FDA, which has previously determined that some peptides lack sufficient safety data. The committee will review seven peptides that have been nominated for inclusion on the FDA’s 503A Bulks List, a list of ingredients that compounding pharmacies may use to prepare customized medications for people under specific legal conditions. The FDA’s experts say there is a lack of evidence on effectiveness and safety to justify letting pharmacies make the peptides, and propose not adding them to the list. The peptides under consideration are BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, and Epitalon. The committee’s recommendations are advisory rather than binding, and the FDA will ultimately decide whether to follow them. Some experts have raised concerns about the safety of using emerging peptides that are still considered experimental, often with labels that say “research use only” or “not for human consumption.” Many people have accessed these peptides online, sometimes from unknown sources, without ever consulting a doctor. Supporters argue that allowing FDA-regulated compounding pharmacies to prepare these medications with a prescription would provide a safer alternative to ordering products online from unregulated vendors. Critics counter that moving the compounds into legitimate pharmacies could create the appearance that they have been proved safe and effective when, in many cases, data from robust clinical trials remains limited. The tension lies at the heart of the upcoming meeting. The future of regulations around peptides may mirror how dietary supplements are currently regulated, suggested Dr. Janet Woodcock, a retired FDA veteran and former principal deputy commissioner. The Alliance for Pharmacy Compounding hopes that the advisory committee will recommend the peptides for pharmacy compounding, which could create a safer pathway for access. Additionally, they argue for a green list of authorized FDA-registered manufacturers of these substances, and enhanced disclosure to patients about the higher risk profile of these peptides. The outcome of this meeting will significantly impact the availability of peptides in the US, and the potential for a safer pathway through compounding pharmacies.
